Nasdaq:US$15.81 (+0.12) | HKEX:HK$24.65 (-0.30) | AIM:£2.29 (-0.01)
News & Presentations
Previous Article   |   Next Article
Presentations | 18 Apr 2023

AACR 2023: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies